Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy.

By A. Banfi, A. Muraglia, B. Dozin, M. Mastrogiacomo, R. Cancedda, R. Quarto. Experimental Hematology, 2000

776 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Aging of mesenchymal stem cells. (2006, background): “In contrast to embryonic stem cells that show no loss of proliferative potency (Rosenberger, 1995), the maximal population doublings MSC have achieved in vitro are reported as 30–40 (Banfi et al., 2000; Baxter et al., 2004; Bruder et al., 1997).”
Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications (2005, background): “…IGF-1, and PDGFs are key factors in supporting MSC ex vivo expansion and maintaining their multilineage potential for further differentiation (Gibbons et al., 1995; Cassiede et al., 1996; Hanada et al., 1997; Banfi et al., 2000; Muraglia et al., 2000; Tsutsumi et al., 2001; Walsh et al., 2003).”
Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process (2008, result): “Our results are in line with similar studies from other groups that demonstrate functional implications on differentiation potential [10], [11], [34], [37].”
Bone tissue engineering: A review in bone biomimetics and drug delivery strategies (2009, background): “of studies have shown that MSCs which have been extensively cultured ex vivo lose their phenotypic behavior (such as osteodifferentiation and bone forming capacity) once implanted in vivo.(33,44,45) Secondary challenges confronted in this approach are related to the relative low concentration of MSC”